{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:56Z","timestamp":1792037096876,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Tobacco Inc."},{"DOI":"10.13039\/100016730","name":"Torii Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016730","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ferric citrate hydrate (FC) is an oral iron-based phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). This post-marketing surveillance study was performed to investigate the long-term safety and effectiveness of FC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, multicenter, observational post-marketing surveillance study was performed in a real-world setting in Japan. The study involved CKD patients with hyperphosphatemia receiving FC who were undergoing either hemodialysis or peritoneal dialysis or were non-dialysis-dependent. Adverse drug reactions, iron- and erythrocyte-related parameters (i.e., levels of serum ferritin, transferrin saturation, and hemoglobin), and serum levels of phosphorus, corrected calcium, and intact parathyroid hormone were monitored for up to 104\u00a0weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Safety was evaluated in 2723 patients. Of these patients, 20.5% discontinued FC because of adverse events, and 3.9% discontinued FC because of unsatisfactory effectiveness. Iron-related parameters gradually increased after the initiation of FC treatment but stabilized after week 36. Effectiveness was analyzed in 2367 patients. Serum phosphorus immediately decreased, and the effect persisted for 104\u00a0weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this 104\u00a0week surveillance study, no new safety concerns were noted. The safety profile was not obviously different from those in pre-approval clinical trials and the 52\u00a0week interim report of this surveillance study. The serum ferritin level of most patients was below the upper limit of the target range, and iron overload risk was not evident. Long-term FC treatment effectively controlled serum phosphorus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-022-02204-1","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T12:03:20Z","timestamp":1646741000000},"page":"688-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-592X","authenticated-orcid":false,"given":"Keitaro","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Susai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"2204_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"2204_CR2","doi-asserted-by":"crossref","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050\u201365.","DOI":"10.1161\/01.HYP.0000102971.85504.7c"},{"key":"2204_CR3","doi-asserted-by":"crossref","unstructured":"Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. REIN Study Group. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22:1923\u201330.","DOI":"10.1681\/ASN.2011020175"},{"key":"2204_CR4","doi-asserted-by":"crossref","unstructured":"Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, et al. PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transpl. 2007;22:2909\u201316.","DOI":"10.1093\/ndt\/gfm286"},{"key":"2204_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2204_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1681\/ASN.2008040349","volume":"20","author":"KL Adeney","year":"2009","unstructured":"Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2204_CR7","first-page":"451","volume":"2013","author":"K Yokoyama","year":"2011","unstructured":"Yokoyama K, Taniguchi M, Fukagawa M. A Japanese approach for CKD-MBD. Kidney Int Suppl. 2011;2013(3):451\u20136.","journal-title":"Kidney Int Suppl"},{"key":"2204_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.jrn.2014.03.006","volume":"24","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr. 2014;24:261\u20137.","journal-title":"J Ren Nutr"},{"key":"2204_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000366482","volume":"128","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Hirakata H. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. Nephron Clin Pract. 2014;128:135\u201340.","journal-title":"Nephron Clin Pract"},{"key":"2204_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543\u201352.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2204_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12185-021-03123-9","volume":"114","author":"N Komatsu","year":"2021","unstructured":"Komatsu N, Arita K, Mitsui H, Nemoto T, Hanaki K. Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. Int J Hematol. 2021;114:8\u201317.","journal-title":"Int J Hematol"},{"key":"2204_CR12","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41598-019-45335-4","volume":"9","author":"K Yokoyama","year":"2019","unstructured":"Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, et al. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep. 2019;9:8877.","journal-title":"Sci Rep"},{"key":"2204_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","volume":"6","author":"S Fishbane","year":"2017","unstructured":"Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 2017;6:1851\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2204_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3109\/0886022X.2014.930491","volume":"36","author":"A Matsuo","year":"2014","unstructured":"Matsuo A, Iida A, Tanimoto M, Matsushita M, Miyamoto K. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats. Ren Fail. 2014;36:1291\u20137.","journal-title":"Ren Fail"},{"key":"2204_CR15","first-page":"457","volume":"40","author":"A Komatsu","year":"2019","unstructured":"Komatsu A, Kido Y, Hanaki K, Orui S, Nishino N, Tan M. Safety and efficacy of ferric citrate hydrate in hyperphosphatemia patients with chronic kidney disease: an interim report on post-marketing surveillance for ferric citrate hydrate. Therapeutic Res. 2019;40:457\u201372 (in Japanese).","journal-title":"Therapeutic Res"},{"key":"2204_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.anndiagpath.2016.10.001","volume":"26","author":"S Ban","year":"2017","unstructured":"Ban S, Suzuki S, Kubota K, Ohshima S, Satoh H, Imada H, et al. Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate. Ann Diagn Pathol. 2017;26:6\u20139.","journal-title":"Ann Diagn Pathol"},{"key":"2204_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3:36.","journal-title":"Ren Replace Ther"},{"key":"2204_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","volume":"99","author":"JL Babitt","year":"2021","unstructured":"Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, et al. Controversies in optimal anemia management: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Int. 2021;99:1280\u201395.","journal-title":"Kidney Int"},{"key":"2204_CR19","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2020101531","volume":"32","author":"M Guedes","year":"2021","unstructured":"Guedes M, Muenz DG, Zee J, Bieber B, Stengel B, Massy ZA, et al. Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia. J Am Soc Nephrol. 2021;32:2020\u201330.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02204-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:05:12Z","timestamp":1655388312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02204-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2204"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02204-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Keitaro Yokoyama has received honoraria from Japan Tobacco Inc., Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd. Teruo Hashimoto, Yuri Okuda, Yu Matsumoto, Ryoichi Yamada, and Hiroyuki Susai are employees of Japan Tobacco Inc. Kyoko Ito and Noriaki Nishino are employees of Torii Pharmaceutical Co., Ltd. This surveillance study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This was an observational post-marketing surveillance study and was conducted in accordance with the Good Post-Marketing Study Practice (GPSP) of the Ministry of Health, Labour and Welfare in Japan. The requirement for informed consent was waived because the intervention was within general clinical practice and the data were anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}